Immune Pharmaceuticals — BIO CEO and Investor Conference 2018
20 slides from Immune Pharmaceuticals's conference presentation, Feb 12, 2018
Slide 1: BIO CEO and Investor Conference
www.immunepharma.com NASDAQ: IMNP BIO CEO and Investor Conference Elliot Maza – Chief Executive Officer February 12, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and oral statements made by representatives of the Company may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company. Actual events or results may differ materially from those
Slide 3: Overview
Overview • Two ongoing phase 2 studies - bullous pemphigoid and ulcerative colitis - Excellent safety and tolerability profile in over 100 subjects exposed - Multiple additional indications include atopic dermatitis, asthma and others • Potential to enter pivotal registration study in 2019 3 Develop
Slide 4: Robust Pipeline Addresses Significant Unmet Needs
Robust Pipeline Addresses Significant Unmet Needs 4 Program Indication Preclinical Phase 1 Phase 2 Phase 3 Bertilimumab Bullous Pemphigoid (BP) Ulcerative Colitis (UC) Allergic Rhinitis (AR) Allergic Conjunctivitis (AC) Atopic Dermatitis (AD) Other Inflammatory Conditions NanoCyclo Atopic Dermatitis
Slide 5: Eotaxin - Implicated in Many Inflammatory Diseases
Eotaxin - 1 Implicated in Many Inflammatory Diseases 5 Gastroenterology Ulcerative Colitis Crohn’s Disease Primary Sclerosing Cholangitis (PSC) Eosinophilic Esophagitis Re s pira tory Asthma Chronic obstructive pulmonary disease (COPD) De rmatology Bullous Pemphigoid Atopic Dermatitis Cutaneous Drug
Slide 6: Bertilimumab Blocks Eotaxin-1
Bertilimumab Blocks Eotaxin - 1 • Bertilimumab is a human antibody with picomolar affinity and high specificity for human eotaxin - 1 • Prevents eotaxin - 1 - induced chemotaxis and shape change of human eosinophils • Pharmacokinetic profile consistent with biweekly dosing • Clean safety profile in
Slide 7: Bullous Pemphigoid
Bullous Pemphigoid 7 1: http://www.orpha.net/consor/cgi - bin/Disease_Search.php?lng=EN&data_id=8663&Disease_Disease_Search_diseaseGroup=bullous - pemphigoid&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Bullous - pemphigoid&title=Bullous - pemphigoid&s earch=Disease_Search
Slide 8: Phase 2 Study in Bullous Pemphigoid - Positive Interim Data from First 6 Subjects
Phase 2 Study in Bullous Pemphigoid - Positive Interim Data from First 6 Subjects 8 Expect to Complete Enrollment and Report Additional BP Data in Q2 2018 Single - arm, open - label phase 2 study ongoing 10 - 15 subjects with moderate - to - extensive disease 3 IV doses Every 2 weeks 84 day follow -
Slide 9: Phase 2 Interim Results Demonstrated Rapid and Sustained Improvement in BPDAI Scores
Phase 2 Interim Results Demonstrated Rapid and Sustained Improvement in BPDAI Scores 9 0 10 20 30 40 50 60 70 0 14 28 42 56 70 84 BPDAI Total Activity Score Study Day BPDAI Total Activity Score First six subjects of a targeted 10 - 15; mean age 76 years 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0 14 28 42
Slide 10: Positive Interim Phase 2 Could Lead to Pivotal Trial
Positive Interim Phase 2 Could Lead to Pivotal Trial • 85% reduction in BPDAI Total Activity Index (p=0.0096) - All subjects achieved a >50% improvement - 4/6 with >90% improvement • Mean initial prednisone dose of 26 mg (0.34 mg/kg) tapered to 9 mg (0.13 mg/kg) (p=0.0145) - Standard regimen would h
Slide 11: Ulcerative Colitis
Ulcerative Colitis 11 1: https://www.crohnsandcolitis.com/ulcerative - colitis Chronic, Inflammatory Bowel Disease Moderate - to - severe disease managed with TNF - blockers or other immunosuppressants • Many patients do not have adequate disease control or experience toxicities Control mAb Anti - e
Slide 12: Bertilimumab Proof of Concept Trial in Ulcerative Colitis
Bertilimumab Proof of Concept Trial in Ulcerative Colitis 12 Randomized, double - blind, placebo - controlled trial 42 Subjects 2:1 randomization Patients selected based on Mayo UC Score and tissue eotaxin - 1 levels Every 2 weeks 90 day follow - up 3 IV doses Additional Efficacy Endpoints: • Mucosa
Slide 13: Additional Bertilimumab Development Plans
Additional Bertilimumab Development Plans • Several opportunities being vetted for next clinical indication - Asthma – lesson learned from IL - 5 inhibitors, which are only active in asthma patients with high eosinophil counts - Severe atopic dermatitis – developing subcutaneous formulation - Severa
Slide 14: NanoCyclo - Topical Cyclosporine
NanoCyclo - Topical Cyclosporine • Alternatives to topical corticosteroids remain in demand • Topical Calcineurin Inhibitors (TCIs) addressed this gap - Topical formulations of systemic immunosuppressants - Protopic® and Elidel® peaked at over $500 mm in WW sales - However, black - box for cancer ri
Slide 15: NanoCyclo - Topical Cyclosporine
NanoCyclo - Topical Cyclosporine • Down - regulates pro - inflammatory cytokines in the skin • Efficacy comparable to topical corticosteroids and TCIs in a human skin model of atopic dermatitis • Produces clinical improvement in mouse models • Intend to pursue 505(b)(2) pathway for atopic dermatitis
Slide 16: Financial Snapshot
Financial Snapshot – NASDAQ: IMNP 16 ~30M ~$17M 1.25M 1: As of February 7, 2018; closing price of $.55 per share Common Shares Outstanding Avg. Volume (3 month) 1 Market Cap. 1 Recent Financing of $ 18 Million Eliminates Debt and Strengthens Balance Sheet
Slide 17: Management Team
Management Team 17 Elliot Maza, JD, CPA - President and CEO Extensive and successful experience in managing micro - cap biotech and drug manufacturing companies Tony Fiorino, MD, PhD - CMO/COO Broad experience in leading clinical - stage biotech companies and a former fund manager well - versed in f
Slide 18: Expected Near-Term Milestones
Bertilimumab • Present interim data as late - breaker at AAD NanoCyclo • Select formulation and begin GMP manufacturing Corporate • Form 10 filing for Cytovia spin - off Bertilimumab • Complete enrollment and report additional BP results • Complete development of new manufacturing process and initia
Slide 19: Investment Highlights
Investment Highlights • Lead program, bertilimumab, in two ongoing phase 2 studies with data expected in 2018 - Potential to enter pivotal registration study in 2019 • Potential to expand bertilimumab into multiple high value indications, including atopic dermatitis and asthma • NanoCyclo, polymer -
Slide 20: Thank You!
www.immunepharma.com NASDAQ: IMNP Thank You!
Immune Pharmaceuticals — BIO CEO and Investor Conference 2018 on 6ix